News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN) and Bristol-Myers Squibb Company (BMY) Resubmit Dapagliflozin New Drug Application for the Treatment of Type 2 Diabetes in the U.S.



7/25/2013 11:29:17 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AstraZeneca and Bristol-Myers Squibb today announced they have resubmitted to the U.S. Food and Drug Administration (FDA), a New Drug Application (NDA) for dapagliflozin for the treatment of adults with type 2 diabetes. The NDA resubmission, which is pending acceptance by the FDA, includes several new studies and additional long-term data (up to four years' duration) from previously submitted studies. Dapagliflozin, an investigational compound, is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2), which works independently of insulin.

Help employers find you! Check out all the jobs and post your resume.

Read at News Release
Read at Reuters


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES